Plasma sphingomyelins increase in pre-diabetic Korean men with abdominal obesity

Seung-Soon Im1, Hyeon Young Park1, Jong Cheol Shon2, In-Sung Chung3, Ho Chan Cho4, Kwang-Hyeon Liu2*, Dae-Kyu Song1*

1 Department of Physiology and Obesity-mediated Disease Research Center, Keimyung University School of Medicine, Daegu, Korea, 2 BK21 Plus KNU Multi-Omics Based Creative Drug Research Team, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Korea, 3 Department of Occupational & Environmental Medicine, Keimyung University School of Medicine, Daegu, Korea, 4 Department of Clinical Endocrinology, Keimyung University School of Medicine, Daegu, Korea

* dstlkh@knu.ac.kr (KHL); dksong@kmu.ac.kr (DKS)

Abstract

Abdominal or visceral obesity is a well-known risk factor for metabolic diseases. However, whether abdominal obesity significantly affects plasma lipid profile during the development of type 2 diabetes has not been fully elucidated. We investigated the differences in plasma lipid concentrations in 63 participants categorized into six groups (middle-aged Korean men); Normal, Pre-diabetes (pre-DM), and Diabetes mellitus (DM) with or without abdominal obesity (AO or lean). The lipidomic profiles were determined by using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Sphingomyelin (SM) levels in plasma were significantly higher in the pre-DM with AO than in pre-DM with lean \((p = 0.021)\). SM concentrations correlated positively with waist-to-hip ratio (WHR) \((r = 0.256, p = 0.044)\), cholesteryl ester (CE) \((r = 0.483, p < 0.0001)\), ceramide \((r = 0.489, p < 0.0001)\) and plasmanyl phosphatidylcholine (PC) \((r = 0.446, p < 0.0001)\). The present study found that pre-diabetic patients with AO were characterized by increased plasma concentrations of SM. Plasma SM levels in individuals with AO may be an early prognostic biomarker to better predict the progression toward type 2 diabetes and metabolic syndrome.

Introduction

Obesity and type 2 diabetes are rapidly emerging as major public health problems worldwide. The rates of diabetes and obesity tended to increase in Korea [1]. Since all obese individuals are not a diabetic, the mechanism of linking obesity to diabetes is not clear yet. Indeed, Asians and Asian Americans have a lower prevalence of obesity as measured by body mass index (BMI) compared with Caucasians, but have a higher percentage of body fat at the same BMI as Caucasians [2]. In 2016, the Korean Diabetes Association reported that 58% of diabetic patients presented abdominal obesity (AO) and a quarter of the adults 30 years or older had pre-diabetes defined as impaired fasting glucose in the 100–125 mg/dL range [3]. Thus, the influence of AO on the risk of diabetes was found to be more important than that of general...
obesity in Asians [4]. In fact, clinical measurements of AO such as waist circumference and waist-to-hip ratio (WHR) are regarded as independent predictors for metabolic syndrome such as diabetes, hypertension, and cardiovascular diseases [5–7]. The Bangladesh study also suggested that high waist circumference and WHR reflecting AO are significant predictors of pre-diabetes [8]. Therefore, identifying AO appears to be particularly important among the Asian population at a risk of type 2 diabetes at normal BMI values [4, 9, 10]. It has been hypothesized that quantitative analysis of plasma metabolites can reveal the precise mechanisms by which or where a specific metabolic pathway is altered and deregulated in pathogenic conditions. Many studies have been conducted to identify predictive biomarkers of diabetic susceptibility. However, no biomarkers explaining the relationship between AO and progression of diabetes are yet available. Moreover, only few studies have used lipidomic analysis to characterize the relationship between AO and progression of diabetes.

Therefore, the aim of the present study was to identify AO-mediated specific biomarker candidates through the analysis of plasma lipids according to the presence or absence of abdominal obesity in normal, pre-diabetic and diabetic patients. To identify early biomarker candidates in plasma of pre-diabetic and diabetic patients with abdominal obesity, we performed a semi-quantitative lipidomic profiling using liquid chromatography-tandem mass spectrometry (LC-MS/MS) as well as routine clinical biochemical analysis of individual plasma samples. Our finding suggests that subjects who have AO may be prevented early from development of diabetes through clinical treatment because they are in the pre-diabetic stage when the serum level of SM rises.

Materials and methods

Study subjects and design

This study was approved by the Institutional Review Boards of Keimyung University Dongsan Medical Center in Korea (2015-03-010) and written informed consents were obtained from all subjects. We conducted surveys and clinical examination of 63 male participants who visited the Keimyung University Dongsan Medical Center for health and medical examination from May 2016 to April 2017. The subjects were divided into three groups based on fasting blood glucose and glycated hemoglobin (HbA1c) levels: patients with type 2 diabetes (DM, $n = 25$) if $FBS > 126$ mg/dL or $HbA1c > 8.0$ mmol/L, pre-diabetes (pre-DM, $n = 18$) if $FBS \leq 110 \pm 5$ mg/dL or $HbA1c \leq 5.7 \pm 0.2$ mmol/L, and non-diabetic control ($n = 20$) if $FBS < 100$ mg/dL or $HbA1c < 5.7$ mmol/L. The optimal cut-off of waist circumference for the criteria of abdominal obesity is 90 cm in men [11].

Anthropometric and clinical measurements

A detailed questionnaire was completed by each of the 63 participating subjects. Information obtained included age, gender, height, weight, blood pressure, smoking history, alcohol consumption, duration of diabetes, and history of hypertension or cardiovascular diseases. All measurements were taken after an 8-h overnight fast. Trained research nurses performed blood pressure as well as anthropometric measurements using standardized protocols. Anthropometric data included height measured by using a stadiometer (FA600, Fanics, Seoul, Korea). Inbody770 (Inbody, Seoul, Korea) was used to measure body weight and body composition. BMI was calculated as weight in kilograms divided by the square of the height in meters. Waist circumference was measured midway between the lower rib margin and iliac crest. Hip circumference was measured at the level of widest circumference over the greater trochanters. WHR was calculated as waist circumference divided by hip circumference. Blood samples were obtained and used for the determination of glucose, insulin, HbA1c, alanine aminotransferase.
(ALT), aspartate aminotransferase (AST), triglycerides (TG), high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol. The biochemical profiles from blood samples, were analyzed by using an automated glycohemoglobin analyzer HLC-723G8 (Tosoh, Tokyo, Japan), clinical chemistry system analyzer ADVIA2400 (SIEMENS, München, Germany), and BIOSEN C-line, clinic (EKF Diagnostic, Barleben, Germany). Plasma samples for lipidomic study were stored at -80°C.

**Reagents**

Lipid standards (phosphatidylycerol (PC) 17:0/14:1, phosphatidylethanolamine (PE) 17:0/14:1, lysoPC (LPC) 17:1, lysoPE (LPE) 17:1, sphingomyelin (SM) d18:1/12:0, ceramide d18:1/12:0, diacylglycerol (DAG) 8:0/8:0, triacylglycerol 15:0/15:0/15:0, and cholesteryl ester (CE) 15:0) were obtained from Avanti Polar Lipids (Alabaster, AL, USA) or Sigma-Aldrich (St. Louis, MO, USA). Lipid internal standard (IS) solutions were stored at -80°C. Ammonium acetate, chloroform, methyl tert-butyl ether (MTBE), and butylated hydroxytoluene were purchased from Sigma Aldrich (St. Louis, MO, USA).

**Lipid extraction**

Plasma lipids were extracted by using the Matyash method with some modifications [12]. Briefly, plasma (10 μL) was aliquoted in an Eppendorf tube containing the internal lipid standard mixture (40–400 ng/mL). Four hundred microliters of ice-cold 75% methanol with 0.1% butylated hydroxytoluene (BHT) was added to the plasma sample. Next, 1 mL MTBE was added, and the mixture was shaken for 1 h at room temperature. For phase separation, 250 μL of water was added, and centrifuged (14,000 x g, 4°C, 15 min). The upper phase was transferred to a new tube, dried under vacuum and reconstituted in 100 μL chloroform/methanol (1:9, v/v).

**LC-MS/MS**

Semi-quantitative lipid profiling was performed by using a Nexera2 LC system (Shimadzu Corporation, Kyoto, Japan) connected to a triple quadrupole mass spectrometer (LC-MS 8040; Shimadzu, Kyoto, Japan) with reversed phase Kinetex C18 column (100 × 2.1 mm, 2.6 μm, Phenomenex, Torrance, CA, USA) for chromatographic separation of lipids. The mobile phase A consisted of water/methanol (1:9, v/v) containing 10 mM ammonium acetate, and the mobile phase B consisted of isopropanol/methanol (5:5, v/v) containing 10 mM ammonium acetate. The gradient elution program was as follows: 0 min (30% B), 0–15 min (95% B), 15–20 min (95% B), and 20–25 min (30% B). The flow rate was set a 200 μL/min. Five microliters of sample were injected for each run. Quantitation was performed by selected reaction monitoring (SRM) of the [M+H]+ (or [M+NH4]+) ion and the related product ion for each lipid. To determine the concentration of each target lipid species, the calculated ratio of target analyte and internal standard (IS) is then multiplied by the concentration of the IS [13–15]. An IS for each lipid class were selected for single-point calibrations of each target lipid species (LPC 17:1, LPC 17:1, LPC 17:1, PC 31:1(17:0/14:1), PC 31:1(17:0/14:1), PC 31:1(17:0/14:1), PE 31:1 (17:0/14:1), PE 31:1(17:0/14:1), SM 30:1(d18:1/12:0), ceramide 15:1, CE 15:0, DAG 16:0(8:0/8:0), and TAG 45:0(15:0/15:0/15:0) for LPC, plasmenyl LPC, LPE, PC, plasmenyl PC, plasmenyl PE, SM, ceramide, CE, DAG, and TAG class, respectively). The SRM transitions and collision energies determined for each lipid are listed in S1 Table. The total ion chromatogram (A) and SRM chromatogram (B) indicating retention time ranges for each lipid species are represented in S1 Fig.
Statistical analysis

Statistical analyses were performed by using SPSS v.23.0 (IBM SPSS Statistics 23, Chicago, IL, USA). The results were expressed as the mean ± standard error (SE). Statistical significance was considered with a two-tailed p-value of < 0.05. The statistical comparison was conducted by using Student’s independent t-tests or Mann–Whitney U-test to compare continuous data between lean and AO groups. Differences among three groups (Normal, pre-DM, and DM) were determined by analysis of variance (ANOVA) followed by Tukey’s honest significant difference test. Spearman’s rank correlation coefficient analysis was carried out to explore correlations between the clinical parameters and the lipid profiles. Only significant correlations were reported in the figures. Correlation matrixes were created to visualize the correlation between biochemical parameters and plasma lipids of the study participants using R (R vision 3.1.2, R Foundation for Statistical Computing, Vienna, Austria).

Results

Clinical characteristics of the study participants

Abdominal obese participants from all three groups had significantly higher anthropometric measurements than lean ones did, namely body weight, BMI, body fat mass, body fat%, waist circumference, and WHR. ALT and AST were significantly elevated in pre-diabetic subjects with AO (p = 0.001 and p = 0.007, respectively) compared to pre-diabetic subjects without AO (Table 1).

Identification of lipids in the human plasma using LC-MS/MS

In general, reversed-phase LC (RPLC), normal-phase (NPLC) and hydrophilic interaction chromatography (HILIC) method have been used for the analysis of lipid mixtures [16]. Among them RPLC has been most widely used for the analysis of complex lipids in various biological samples [16]. In addition, the analysis time in NPLC and HILIC are typically longer (30–60 min) than RPLC [16]. Therefore, we used RPLC method for the analysis of plasma lipids in this study [17].

The mass spectrometry method was based on the automated acquisition of 204 SRM transitions (S1 Table). Specific diagnostic Q1 and Q3 ions were used to quantify each lipid class. [M +NH₄]⁺ ion for neutral lipids, including DAG, TAG, and CE were selected as Q1 ion, whereas [M+H]⁺ ion for the other lipids were selected. Lipid class specific ions or fragment ion produced from the loss of fatty acyl chain were selected as Q3 ion for the quantitation of each lipid. For example, five PC species (LPC, PC, plasmanyl PC, plasmenyl PC, and SM), two LPC species (plasmanyl LPC and plasmenyl LPC), CE, and ceramide were recorded by Q3 ion at m/z 184, 104, 369, and 264 corresponding to phosphocholine, choline, cholesterol-H₂O, and sphingosine-2H₂O, respectively [18, 19]. The fragment ions from the loss of the phosphoethanolamine group (-141) and fatty acyl chain were selected as Q3 ion for PE (LPE and PE) and neutral lipids (DAG and TAG), respectively [20]. For LPC, PC, plasmanyl PC, plasmenyl PC, and SM species, the transition from the protonated molecular ion ([M+H]⁺) to the polar head fragment ion (m/z 184, phosphocholine) was recorded for the quantitation [21]. Regarding DAG and TAG species, the transition from the ammoniated molecular ion ([M+NH₄]⁺) to the fragment ions from the loss of fatty acyl chain were recorded (S1 Fig).

Effect of abdominal obesity on plasma lipid levels

Of the 12 lipid classes, the levels of total TAG were significantly elevated by AO in normal subjects (p = 0.025), whereas the levels of the other lipids were not significantly altered by AO.
Table 1. Clinical characteristics of the study participants.

|                        | Lean (n = 10) | AO (n = 10) | p-value | Lean (n = 8) | AO (n = 10) | p-value | Lean (n = 12) | AO (n = 13) | p-value |
|------------------------|--------------|-------------|---------|--------------|-------------|---------|--------------|-------------|---------|
| Age (year)             | 39.9 ± 1.0   | 42.4 ± 2.4  | 0.347   | 44.9 ± 2.0   | 43.9 ± 1.1  | 0.660   | 51.7 ± 1.9   | 49.1 ± 2.4  | 0.583   |
| Height (cm)            | 173.8 ± 1.7  | 174.9 ± 1.4 | 0.629   | 170.4 ± 1.6  | 175.0 ± 1.7 | 0.071   | 168.7 ± 1.7  | 175.0 ± 1.8 | 0.016   |
| Weight (kg)            | 62.1 ± 1.4   | 75.0 ± 1.4  | 0.001   | 70.8 ± 2.6   | 80.2 ± 1.9  | 0.009   | 67.3 ± 1.9   | 84.8 ± 2.6  | 0.001   |
| BMI (kg/m2)            | 21.1 ± 0.3   | 24.4 ± 0.2  | 0.001   | 24.6 ± 0.5   | 26.3 ± 0.5  | 0.025   | 23.8 ± 0.4   | 27.7 ± 0.7  | 0.001   |
| Soft Lean Mass (kg)    | 51.4 ± 1.5   | 52.4 ± 1.2  | 0.436   | 53.4 ± 1.8   | 57.4 ± 1.6  | 0.116   | 51.9 ± 2.1   | 55.4 ± 3.4  | 0.388   |
| Fat Free Mass (kg)     | 54.3 ± 1.6   | 55.5 ± 1.3  | 0.393   | 56.4 ± 1.9   | 60.8 ± 1.7  | 0.115   | 54.9 ± 2.3   | 58.5 ± 3.5  | 0.393   |
| Skeletal Muscle Mass (kg)| 30.6 ± 1.0  | 31.2 ± 0.8  | 0.606   | 31.8 ± 1.1   | 34.5 ± 1.0  | 0.098   | 30.5 ± 1.2   | 42.8 ± 10.1 | 0.250   |
| Body Fat Mass (kg)     | 9.3 ± 0.3    | 19.3 ± 0.6  | 0.001   | 15.0 ± 1.0   | 19.7 ± 0.8  | 0.002   | 14.6 ± 1.0   | 34.0 ± 11.5 | 0.115   |
| Body fat (%)           | 14.8 ± 1.0   | 25.9 ± 0.8  | 0.001   | 21.0 ± 0.9   | 24.5 ± 1.0  | 0.021   | 21.2 ± 1.3   | 27.9 ± 1.9  | 0.010   |
| Waist (cm)             | 76.4 ± 0.6   | 92.1 ± 0.7  | 0.001   | 84.8 ± 1.1   | 92.8 ± 0.8  | 0.001   | 84.2 ± 1.2   | 97.0 ± 1.8  | 0.001   |
| Hip (cm)               | 92.7 ± 0.6   | 98.1 ± 0.5  | 0.001   | 97.5 ± 1.3   | 101.6 ± 0.9 | 0.018   | 96.2 ± 1.2   | 100.0 ± 1.6 | 0.068   |
| WHR                    | 0.82 ± 0.01  | 0.94 ± 0.01 | 0.001   | 0.87 ± 0.01  | 0.92 ± 0.01 | 0.004   | 0.88 ± 0.01  | 0.97 ± 0.02 | 0.001   |
| HbA1c (%)              | 5.12 ± 0.08  | 5.25 ± 0.1  | 0.247   | 5.86 ± 0.1   | 5.96 ± 0.05 | 0.234   | 7.91 ± 0.41  | 8.60 ± 0.46 | 0.275   |
| FBS (mg/dL)            | 85.0 ± 2.0   | 92.3 ± 1.7  | 0.011   | 105.1 ± 2.3  | 106.2 ± 1.7 | 0.829   | 133.7 ± 11.9 | 154.4 ± 9.9 | 0.076   |
| ALT (IU/L)             | 15.2 ± 2.5   | 38.8 ± 13.8 | 0.075   | 16.3 ± 2.4   | 34.4 ± 4.4  | 0.001   | 22.4 ± 4.1   | 51.4 ± 15.0 | 0.083   |
| AST (IU/L)             | 19.6 ± 1.2   | 28.3 ± 5.4  | 0.393   | 18.1 ± 1.2   | 24.9 ± 1.8  | 0.007   | 23.4 ± 2.3   | 36.8 ± 7.2  | 0.280   |
| Cholesterol (mg/dL)    | 178.5 ± 5.9  | 208.5 ± 8.3 | 0.009   | 219.4 ± 13.9 | 220.6 ± 8.6 | 0.939   | 164.2 ± 13.8 | 180.4 ± 14.8 | 0.442   |
| TG (mg/dL)             | 99.1 ± 12.7  | 175.6 ± 24.5| 0.015   | 197.8 ± 53.0 | 240.1 ± 41.6| 0.360   | 171.5 ± 27.1| 232.8 ± 54.4| 0.334   |
| HDL (mg/dL)            | 53.7 ± 3.7   | 45.7 ± 3.2  | 0.121   | 45.3 ± 1.9   | 41.3 ± 2.3  | 0.274   | 41.7 ± 2.7   | 44.2 ± 3.8  | 0.650   |
| LDL (mg/dL)            | 103.7 ± 7.5  | 128.5 ± 6.8 | 0.025   | 139.6 ± 10.4 | 137.0 ± 8.0 | 0.848   | 91.4 ± 10.7  | 97.8 ± 10.4 | 0.675   |
| Creatine (mg/dL)       | 0.88 ± 0.02  | 0.9 ± 0.03  | 0.853   | 0.88 ± 0.06  | 0.91 ± 0.03 | 0.594   | 0.92 ± 0.06  | 0.85 ± 0.04 | 0.318   |

Values are given as mean ± SE. Significant differences between lean subjects and subjects with abdominal obesity (AO) were analyzed by Student’s t-test or Mann-Whitney. Bold font indicates significance at p < 0.05. Abbreviations: BMI, body mass index; WHR, waist to hip ratio; HbA1c, hemoglobin A1c; FBS, fasting blood sugar; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TG, triglyceride; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol.

https://doi.org/10.1371/journal.pone.0213285.t001

The levels of total SM were significantly increased in the pre-diabetic subjects with AO compared to the pre-diabetic subjects without AO (p = 0.019) (Fig 1A). Otherwise, the other lipids were not significantly altered by AO (Table 2). We further examined the change of 17 individual SM species among the six groups. Higher concentrations (> 20 μM) of SM 34:1, 36:1, 38:1, 40:1, 40:2, 42:2, and 42:3 were found in the plasma. Seven SM species (34:2, 36:0, 36:1, 36:2, 38:1, 38:2, and 40:1) were significantly increased in pre-diabetic subjects with AO compared with the pre-diabetic subjects without AO (Fig 1B). In addition, Pre-DM patients with AO had significantly higher levels of SM36:1, SM38:1 and SM40:1 than normal subjects with AO (Table 3). Taken together, these data suggest that SM36:1, SM38:1 and SM40:1 among lipid species might be putative diagnostic markers in pre-diabetic patients with AO.

Correlation among biochemical parameters and plasma lipids

The Spearman’s correlation coefficients between the anthropometric measures and biochemical parameters with 12 lipid classes. A correlation matrix was computed for all participants (n = 63). Interestingly, LPC and LPE had a negatively correlation with classical diagnostic markers of diabetes or pre-diabetes like FBS and HbA1c. Total SM was positively correlated with WHR and 3 lipid molecular species, such as CE, ceramide and plasmacyl PC (Fig 2). This observation provides additional evidence that SM might be a putative mediator between abdominal obesity and pre-diabetes. Total SM showed a moderate correlation with CE.
Table 2. Plasma lipid profiles.

| Lipid (μM)       | Normal (n = 10) | Pre-diabetes (n = 8) | Diabetes (n = 12) |
|------------------|-----------------|----------------------|-------------------|
|                  | Lean (n = 10)   | AO (n = 10)          | Lean (n = 12)     |
|                  | Lean (n = 8)    | AO (n = 10)          | AO (n = 13)       |
|                  | p-value         | p-value              | p-value           |
| TAG              | 314.1±38.6      | 526.1±74.5           | 593.2±133.9       | 0.025 |
|                  | 577.3±129.0     | 0.341                | 627.0±95.8        | 0.644 |
|                  | 616.±109.8      |                      | 616.±109.8        |        |
| DAG              | 9.8±1.3         | 14.0±2.1             | 17.5±3.5          | 0.105 |
|                  | 17.9±2.9        | 0.917                | 25.9±6.4          | 0.605 |
|                  | 26.9±7.5        |                      | 26.9±7.5          |        |
| SM               | 386.7±9.7       | 410.8±16.4           | 396.3±12.3        | 0.221 |
|                  | 467.0±20.7      | 0.019                | 380.1±29.5        | 0.711 |
|                  | 393.8±22.3      |                      | 393.8±22.3        |        |
| LPE              | 9.3±0.2         | 3±0±0.2              | 3.6±0.3           | 0.448 |
|                  | 3.8±0.3         | 0.460                | 2.6±0.4           | 0.689 |
|                  | 2.4±0.2         |                      | 2.4±0.2           |        |
| Ceramide         | 1408.8±37.2     | 1503.2±74.9          | 1633.9±124.9      | 0.165 |
|                  | 1772.0±109.8    | 0.418                | 159.1±102.2       | 0.390 |
|                  | 1640.±108.3     |                      | 1640.±108.3       |        |
| CE               | 14957.1±438.6   | 15609.7±618.9        | 15791.3±514.8     | 0.177 |
| SM               | 514.8±0.01      |                      | 103086±1394.6     | 0.786 |
| LPE              | 1394.6±10877.7  | 108771±1318.5        | 1400.±102.2       | 0.390 |
| Plasmenyl PE     | 142.9±2.2       | 154.9±7.3            | 178.7±8.8         | 0.418 |
|                  | 224.2±20.5      | 0.482                | 224.2±20.5        | 0.482 |
| LPC              | 331.6±12.8      | 318.6±15.7           | 321.8±29.3        | 0.377 |
|                  | 293.4±21.8      | 0.439                | 247.5±25.6        | 0.668 |
| Plasmanyl PC     | 27.7±0.8        | 30.0±2.7             | 30.8±1.5          | 0.348 |
|                  | 29.0±1.5        | 0.438                | 26.1±1.8          | 0.668 |
|                  | 27.3±2.3        |                      | 27.3±2.3          |        |
| PC               | 1408.8±37.2     | 1503.2±74.9          | 1633.9±124.9      | 0.165 |
| SM               | 1394.6±10877.7  | 108771±1318.5        | 1400.±102.2       | 0.390 |
| LPE              | 142.9±2.2       | 154.9±7.3            | 178.7±8.8         | 0.418 |
| Plasmenyl PE     | 12.1±1.1        | 15.9±1.8             | 16.4±1.5          | 0.259 |
|                  | 14.1±1.4        | 0.460                | 17.1±1.3          | 0.792 |
|                  | 18.3±3.2        |                      | 18.3±3.2          |        |

Values are given as mean ± SE. Significant differences between lean and abdominal obesity groups were analyzed by Student’s t-test or Mann-Whitney. Bold font indicates significance at p < 0.05. Abbreviations: TAG, triacylglycerol; DAG, diacylglycerol; SM, sphingomyelin; CE, cholesteryl esters; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; Plasmenyl PC, plasmenyl phosphatidylcholine; Plasmanyl PC, plasmanyl phosphatidylcholine; PE, phosphatidylethanolamine; LPE, lysophosphatidylethanolamine; Plasmenyl PE, plasmenyl phosphatidylethanolamine.

https://doi.org/10.1371/journal.pone.0213285.t002

Discussion

According to a recent trend of type 2 diabetes in Korea, the prevalence of diabetes is increasingly shifting to obese people, and an inverse linear relationship was detected between BMI

(r = 0.483, p < 0.0001), ceramide (r = 0.489, p < 0.0001) and plasmanyl PC (r = 0.446, p < 0.0001), and a weak correlation with WHR (r = 0.256, p = 0.044) (Fig 3).
and age at diabetes diagnosis among newly diagnosed patients [1]. Nevertheless, there are many non-obese but metabolically unhealthy individuals. Previous research demonstrated that the risk of type 2 diabetes starts at a lower BMI for Asians than for Europeans [22]. Lear et al. determined that healthy Chinese and South Asian individuals present with more visceral adipose tissue than Europeans with the same BMI or waist circumference [23]. Mechanistic studies revealed that visceral adiposity is strongly associated with systemic insulin resistance, which may be one of the key pathophysiological processes in the development of diabetes [2, 24, 25]. The accumulation of visceral and omental fat tissue may induce local inflammation and release various adipocytokines, leading to systemic insulin resistance [2].

In this study, we report the results of plasma lipidomic analysis of 63 participants categorized as normal, pre-diabetic, and diabetic subjects with or without AO. Interestingly, plasma SM levels (SM 36:1, SM 38:1, and SM 40:1), which are related with fatty liver and insulin resistance as well as obesity, were significantly elevated in pre-diabetic individuals with AO when compared to normal individuals with AO or pre-diabetic without AO (Fig 1B and Table 3). Even though these findings were similar with previous studies reported that serum SM species (SM 36:1, 38:1, 40:1, and 42:1) were high in the obese groups [26, 27], our study found that SM species level was significantly increased in pre-diabetic patients with AO compared to pre-diabetic individuals without AO. The results suggest that the abdominal fat accumulation in Korean patient might enhance increase of SM secretion uniquely in pre-diabetic patient than in diabetic patients.

SM is one of the abundant lipids in sphingolipid species and plays major functional roles in animal plasmalemma and membranes of cellular organelles as well as a membrane lipid component per se [28, 29]. SM has a higher concentration than ceramide, which means that SM may act as a pool for the rapid generation of ceramide due to SM hydrolysis by sphingomyelinas. The cited authors also found that high-fat diet feeding significantly increased SM level

| Table 3. Sphingomyelin species profiles. |
|------------------------------------------|
| SM (µM) | Lean (n = 10) | AO (n = 10) | p-valuea | Lean (n = 8) | AO (n = 10) | p-valuea | Lean (n = 12) | AO (n = 13) | p-valuea | (Normal+AO vs. Pre-DM+AO) |
|---------|----------------|-------------|----------|-------------|-------------|----------|-------------|-------------|----------|--------------------------|
| SM 32:1 | 9.9±0.18       | 11.1±0.87   | 0.353    | 12.0±0.67   | 13.3±0.89   | 0.297    | 9.0±0.92    | 10.1±0.81   | 0.225    | 0.095                    |
| SM 32:2 | 0.82±0.05      | 0.95±0.06   | 0.105    | 0.83±0.05   | 0.98±0.05   | 0.050    | 0.63±0.05   | 0.67±0.07   | 0.622    | 0.698                    |
| SM 34:0 | 5.8±0.24       | 6.0±0.27    | 0.142    | 5.6±0.30    | 6.1±0.46    | 0.740    | 6.0±0.52    | 6.0±0.51    | 0.971    | 0.825                    |
| SM 34:1 | 121.1±3.11     | 119.0±4.09  | 0.681    | 117.8±4.10  | 135.6±6.91  | 0.067    | 117.3±10.23 | 123.5±6.04  | 0.604    | 0.053                    |
| SM 34:2 | 13.6±0.42      | 14.8±0.47   | 0.069    | 13.5±0.36   | 16.5±0.91   | 0.019    | 13.0±0.68   | 14.6±0.79   | 0.135    | 0.127                    |
| SM 36:0 | 0.83±0.09      | 1.67±0.14   | 0.001    | 1.23±0.16   | 1.94±0.23   | 0.037    | 1.68±0.24   | 1.74±0.31   | 0.871    | 0.336                    |
| SM 36:1 | 24.0±1.43      | 27.1±1.53   | 0.165    | 25.1±1.32   | 32.9±1.25   | 0.001    | 26.0±2.1    | 27.3±2.31   | 0.687    | 0.009                    |
| SM 36:2 | 8.7±0.55       | 9.9±0.52    | 0.111    | 7.9±0.48    | 11.5±0.61   | 0.001    | 8.8±0.55    | 9.9±0.93    | 0.347    | 0.071                    |
| SM 36:3 | 0.63±0.04      | 0.66±0.05   | 0.643    | 0.61±0.03   | 0.76±0.05   | 0.088    | 0.55±0.13   | 0.56±0.05   | 0.793    | 0.191                    |
| SM 38:1 | 20.7±1.24      | 24.6±1.37   | 0.049    | 23.2±1.31   | 28.9±1.29   | 0.009    | 20.3±1.73   | 20.8±1.99   | 0.856    | 0.036                    |
| SM 38:2 | 7.7±0.52       | 8.8±0.47    | 0.105    | 7.4±0.50    | 9.1±0.45    | 0.024    | 7.0±0.39    | 7.1±0.65    | 0.904    | 0.650                    |
| SM 38:3 | 0.43±0.03      | 0.53±0.04   | 0.089    | 0.53±0.04   | 0.48±0.02   | 0.364    | 0.43±0.04   | 0.47±0.04   | 0.490    | 0.343                    |
| SM 40:1 | 39.4±2.3       | 45.0±2.0    | 0.080    | 42.9±2.08   | 55.5±2.70   | 0.004    | 37.6±4.04   | 39.9±3.90   | 0.694    | 0.006                    |
| SM 40:2 | 31.9±1.3       | 34.8±1.5    | 0.170    | 32.1±1.43   | 37.1±2.02   | 0.083    | 27.7±2.09   | 27.5±2.44   | 0.943    | 0.378                    |
| SM 40:3 | 2.9±0.16       | 3.09±0.16   | 0.362    | 3.1±0.18    | 3.06±0.15   | 0.735    | 2.4±0.24    | 2.5±0.18   | 0.705    | 0.895                    |
| SM 42:2 | 68.2±2.16      | 72.4±3.84   | 0.393    | 73.0±2.67   | 81.0±4.10   | 0.159    | 73.0±6.30   | 72.8±4.75   | 0.976    | 0.140                    |
| SM 42:3 | 30.6±0.80      | 30.4±1.51   | 0.899    | 29.6±0.92   | 32.3±1.66   | 0.229    | 28.5±2.29   | 28.5±1.74   | 0.994    | 0.423                    |

Values are given as mean ± SE. Differences between two groups were tested by Student’s t-test or Mann-Whitney. p-values were derived from Normal + AO vs. Pre-DM + AO. Bold font indicates significance at p < 0.05.

https://doi.org/10.1371/journal.pone.0213285.t003
in the blood and various tissues such as the liver, adipose tissue and heart [30–34]. Consistently, reducing plasma SM levels increased insulin sensitivity in sphingomyelin synthase 2 (Sms2) knockout mice [35]. Taken together, these findings suggest that SM can induce systemic insulin resistance and thus glucose intolerance. The present findings further suggest that increased visceral fat accumulation may be a cause of increased plasma SM levels. Therefore, the detection of high plasma levels of SM in individuals with AO may be an early sign of pre-diabetes and may be a biomarker of diabetes development [36]. General or systemic obesity determined by BMI and total body fat mass is known as a sign for insulin resistance in the early progression of diabetes [37]. In addition, we hypothesize that local omental or visceral fat

---

**Fig 2. Correlation matrix for biochemical characteristics and plasma lipid metabolites across all participants.** The correlations were obtained by deriving Pearson’s correlation coefficients. Red represents a positive correlation and blue represents a negative correlation.

https://doi.org/10.1371/journal.pone.0213285.g002
accumulation with increased plasma SM levels might be also a biomarker of pre-diabetes. As all lipids are not equally affected by obesity, further studies are warranted to determine the mechanism underlying the increase in SM and how SM induces glucose intolerance in subjects with diabetes with AO [38–40]. The link between SM and diabetes has not been clearly elucidated, but previous data have shown that clear synthesis and apoptosis in apoE knockout mice result in increased SM content in lipoproteins [41]. As the SM content of slowly removed residual lipoproteins increases, the susceptibility to arterial wall sphingomyelinase, which plays an important role in converting the sphingomyelin into ceramide, is decreased, leading to an increase in plasma SM level and increase of incidence of atherosclerosis.

In the pre-DM group, AO was also associated with higher plasma AST and ALT levels, reflecting fatty liver and hepatic lipotoxicity. AST and ALT levels correlated positively with obesity-related parameters such as body fat mass and percentage body fat as well as with AO-related waist circumference. Increased visceral fat, having greater lipolytic potential, may result

![Graphs showing correlations between total sphingomyelin (SM) level and various parameters in different groups of participants.](https://doi.org/10.1371/journal.pone.0213285.g003)
in increased delivery of free fatty acid to the liver, which may in turn lead to fatty liver, hepatic insulin resistance and liver damage [42, 43].

In conclusion, the data demonstrated a greater difference in SM species in pre-diabetic subjects with AO. SM levels in the plasma may be an important predictor of early diabetes in Korean men with AO and might be useful to monitor disease progression. Under abdominal obesity condition, identifying pre-diabetes may help develop preventative strategies or better therapeutic approaches based on specific pathogenic mechanisms [44]. This finding should be confirmed in prospective studies with a larger sample size and a multicenter study. Further study is required at a molecular level to figure out an underlying mechanism of lipid metabolites and their enzymes.

Supporting information
S1 Table. The SRM transitions and collision energies determined for each lipid. (XLSX)
S1 Fig. The total ion chromatogram (A) and SRM chromatogram (B) of various lipids in human plasma. (TIF)

Author Contributions
Conceptualization: Seung-Soon Im.
Data curation: Seung-Soon Im, In-Sung Chung, Ho Chan Cho.
Formal analysis: Seung-Soon Im, Hyeon Young Park, Jong Cheol Shon.
Methodology: Seung-Soon Im.
Validation: In-Sung Chung, Ho Chan Cho.
Writing – original draft: Seung-Soon Im.
Writing – review & editing: Kwang-Hyeon Liu, Dae-Kyu Song.

References
1. Ha KH, Kim DJ. Trends in the Diabetes Epidemic in Korea. Endocrinol Metab. 2015; 30(2):142–6.
2. Hayashi T, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. Diabetes. 2008; 57(5):1269–75. Epub 2008/02/27. https://doi.org/10.2337/db07-1378 PMID: 18299316
3. KoreanDiabetesAssociation. Diabetes Fact Sheet in Korea 2016 [Internet]: Korean Diabetes Association; 2016. Available from: http://www.diabetes.or.kr/bbs/index.html?code=e_resource&category=1.
4. Lee YH, Bang H, Kim HC, Kim HM, Park SW, Kim DJ. A simple screening score for diabetes for the Korean population: development, validation, and comparison with other scores. Diabetes care. 2012; 35(8):1723–30. Epub 2012/06/13. https://doi.org/10.2337/dc12-1378 PMID: 22688547
5. Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. The American journal of clinical nutrition. 2006; 84(3):483–9. Epub 2006/09/09. https://doi.org/10.1093/ajcn/84.3.483 PMID: 16980160
6. Castro AVB, Kolka CM, Kim SP, Bergman RN. Obesity, insulin resistance and comorbidities–Mechanisms of association. Arquivos brasileiros de endocrinologia e metabolologia. 2014; 58(6):600–9. PMC4423826 PMID: 25211442
7. Donohoe CL, Doyle SL, Reynolds JV. Visceral adiposity, insulin resistance and cancer risk. Diabetology & Metabolic Syndrome. 2011; 3:12–. https://doi.org/10.1186/1758-5996-3-12 PMC3145556 PMID: 21696633
8. Alam DS, Talukder SH, Chowdhury MAH, Siddiquee AT, Ahmed S, Pervin S, et al. Overweight and abdominal obesity as determinants of undiagnosed diabetes and pre-diabetes in Bangladesh. BMC Obesity. 2016; 3(1):19. https://doi.org/10.1186/s40608-016-0099-z PMID: 27004127

9. Hsu WC, Araneta MRG, Kanaya AM, Chiang JL, Fujimoto W. BMI Cut Points to Identify At-Risk Asian Americans for Type 2 Diabetes Screening. Diabetes care. 2015; 38(1):150–8. https://doi.org/10.2337/dc14-2391 PMID: 25538311

10. Kim DM, Ahn CW, Nam SY. Prevalence of obesity in Korea. Obesity reviews: an official journal of the International Association for the Study of Obesity. 2005; 6(2):117–21. Epub 2005/04/20. https://doi.org/10.1111/j.1467-789X.2005.00173.x PMID: 15836462

11. Yoon YS, Oh SW. Optimal Waist Circumference Cutoff Values for the Diagnosis of Abdominal Obesity in Korean Adults. Endocrinology and Metabolism. 2014; 29(4):418–26. https://doi.org/10.3803/EnM.2014.29.4.418 PMC4285028 PMID: 25559570

12. Chen S, Hoene M, Li J, Li Y, Zhao X, Haring HU, et al. Simultaneous extraction of metabolome and lipidome with methyl tert-butyl ether from a single small tissue sample for ultra-high performance liquid chromatography/mass spectrometry. Journal of chromatography A. 2013; 1298:9–16. Epub 2013/06/08. https://doi.org/10.1016/j.chroma.2013.05.019 PMID: 23743007

13. Bure C, Ayciriex S, Testet E, Schmitter JM. A single run LC-MS/MS method for phospholipidomics. Analytical and bioanalytical chemistry. 2013; 405(1):203–13. Epub 2012/10/16. https://doi.org/10.1007/s00216-012-6466-9 PMID: 23064709

14. Lee JW, Mok HJ, Lee DY, Park SC, Kim GS, Lee SE, et al. UPLC-QqQ/MS-Based Lipidomics Approach To Characterize Lipid Alterations in Inflammatory Macrophages. Journal of proteome research. 2017; 16(4):1460–9. Epub 2017/03/03. https://doi.org/10.1021/acs.jproteome.6b00684 PMID: 28251853

15. Xia YQ, Jemal M. Phospholipids in liquid chromatography/mass spectrometry bioanalysis: comparison of three tandem mass spectrometric techniques for monitoring plasma phospholipids, the effect of mobile phase composition on phospholipid elution and the association of phospholipids with matrix effects. Rapid communications in mass spectrometry. RCM. 2009; 23(14):2125–38. Epub 2009/06/12. https://doi.org/10.1002/rcm.4121 PMID: 19517478

16. Cajka T, Fiehn O. Comprehensive analysis of lipids in biological systems by liquid chromatography-mass spectrometry. Trends in analytical chemistry: TRAC. 2014; 61:192–206. https://doi.org/10.1016/j.trac.2014.04.017 PMID: 25309011

17. Hammad LA, Cooper BS, Fisher NP, Montooth KL, Karty JA. Profiling and quantification of Drosophila melanogaster lipids using liquid chromatography/mass spectrometry. Rapid communications in mass spectrometry: RCM. 2011; 25(19):2959–68. Epub 2011/09/14. https://doi.org/10.1002/rcm.5187 PMID: 21913275

18. Bielawski J, Pierce JS, Snider J, Rembiesa B, Szulc ZM, Bielawski A. Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Advances in experimental medicine and biology. 2010; 688:46–59. Epub 2010/10/06. PMID: 20916455

19. Shon JC, Shin HS, Seo YK, Yoon YR, Shin H, Liu KH. Direct infusion MS-based lipid profiling reveals the pharmacological effects of compound K-reinforced ginsenosides in high-fat diet induced obese mice. Journal of agricultural and food chemistry. 2015; 63(11):2919–29. Epub 2015/03/07. https://doi.org/10.1021/jf506216p PMID: 25744175

20. Park SM, Byeon SK, Sung H, Cho SY, Seong JK, Moon MH. Lipidomic Perturbations in Lung, Kidney, and Liver Tissues of p53 Knockout Mice Analyzed by Nanoflow UPLC-ESI-MS/MS. Journal of proteome research. 2016; 15(10):3763–72. Epub 2016/09/02. https://doi.org/10.1021/acs.jproteome.6b00566 PMID: 27581229

21. Zacek P, Bukowski M, Rosenberger TA, Picklo M. Quantitation of isobaric phosphatidylcholine species in human plasma using a hybrid quadrupole linear ion-trap mass spectrometer. Journal of lipid research. 2016; 57(12):2225–34. Epub 2016/10/01. https://doi.org/10.1194/jlr.D070656 PMID: 27688258

22. Huxley R, James WP, Barzi F, Patel JV, Lear SA, Suriyawongpaisal P, et al. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obesity reviews: an official journal of the International Association for the Study of Obesity. 2008; 9 Suppl 1:S1–61. Epub 2008/03/01. https://doi.org/10.1111/j.1467-789X.2007.00439.x PMID: 18307700

23. Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL. Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). The american journal of clinical nutrition. 2007; 86(2):353–9. Epub 2007/08/09. https://doi.org/10.1093/ajcn/86.2.353 PMID: 17684205

24. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A, et al. Hypoadiponecinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism: clinical and experimental. 2003; 52(10):1274–8. Epub 2003/10/18. PMID: 14564678
25. Son JW, Park C-Y, Kim S, Lee H-K, Lee Y-S. Changing Clinical Characteristics according to Insulin Resistance and Insulin Secretion in Newly Diagnosed Type 2 Diabetic Patients in Korea. Diabetes Metab J. 2015; 39(5):387–94. https://doi.org/10.4093/dmj.2015.39.5.387 PMID: 26566496

26. Hanamatsu H, Ohnishi S, Sakai S, Yuyama K, Mitsutake S, Takeda H, et al. Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults. Nutrition & diabetes. 2014; 4:e141. Epub 2014/10/21. https://doi.org/10.1038/nutdi.2014.38 PMID: 25329603

27. Mitsutake S, Zama K, Yokota H, Yoshida T, Tanaka M, Mitsu M, et al. Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes. The Journal of biological chemistry. 2011; 286(32):28544–55. Epub 2011/06/15. https://doi.org/10.1074/jbc.M111.255646 PMID: 21669879

28. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature reviews Molecular cell biology. 2008; 9(2):139–50. Epub 2008/01/25. https://doi.org/10.1038/nrm2329 PMID: 18216770

29. Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. The Journal of biological chemistry. 2000; 275(23):17221–4. Epub 2000/04/20. https://doi.org/10.1074/jbc. R000005200 PMID: 10770957

30. Kurek K, Piotrowska DM, Wiesiolek-Kurek P, Lukaszuk B, Chabowski A, Gorski J, et al. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver international: official journal of the International Association for the Study of the Liver. 2014; 34 (7):1074–83. Epub 2013/10/11. https://doi.org/10.1111/liv.12331 PMID: 24106929

31. Chocian G, Chabowski A, Zendzian-Piotrowska M, Harasim E, Lukaszuk B, Gorski J. High fat diet induces ceramide and sphingomyelin formation in rat’s liver nuclei. Molecular and cellular biochemistry. 2010; 340(1–2):125–31. Epub 2010/02/23. https://doi.org/10.1007/s11010-010-0409-6 PMID: 20174962

32. Turner N, Kowalski GM, Leslie SJ, Risis S, Yang C, Lee-Young RS, et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia. 2013; 56(7):1638–48. Epub 2013/04/27. https://doi.org/10.1007/s00125-013-2913-1 PMID: 23620060

33. Eisinger K, Liebisch G, Schmitz G, Aslanidis C, Krautbauer S, Buechler C. Lipidomic analysis of serum and subcutaneous fat. Journal of biologica l chemistry. 2011; 286(32):28544–55. Epub 2011/06/15. https://doi.org/10.1074/jbc.M111.255646 PMID: 21669879

34. Son JW, Park C-Y, Kim S, Lee H-K, Lee Y-S. Changing Clinical Characteristics according to Insulin Resistance and Insulin Secretion in Newly Diagnosed Type 2 Diabetic Patients in Korea. Diabetes Metab J. 2015; 39(5):387–94. https://doi.org/10.4093/dmj.2015.39.5.387 PMID: 26566496

35. Kim SJ, Kim SH, Kim JH, Hwang S, Yoo HJ. Understanding Metabolomics in Biomedical Research. Endocrinology and metabolism (Seoul, Korea). 2016; 31(1):7–16. Epub 2015/12/18. https://doi.org/10.3390/EnM.2016.31.1.7 PMID: 26676338

36. Pietilainen KH, Sysi-Aho M, Rissanen A, Seppanen-Laakso T, Yki-Jarvinen H, Kaprio J, et al. Obesity is associated with changes in the serum lipid profile independent of genetic effects—a monozygotic twin study. PloS one. 2007; 2(2):e218. Epub 2007/02/15. https://doi.org/10.1371/journal. pone.0000218 PMID: 17299598

37. Nam M, Choi MS, Jung S, Jung Y, Choi JY, Ryu DH, et al. Lipidomic Profiling of Liver Tissue from Obesity-Prone and Obesity-Resistant Mice Fed a High Fat Diet. Sci Rep. 2015; 5:16984. Epub 2015/11/26. https://doi.org/10.1038/srep16984 PMID: 26592433

38. Park M, Wu D, Park T, Choi CS, Li RK, Cheng KK, et al. APPL1 transgenic mice are protected from high-fat diet-induced heart dysfunction. American journal of physiology Endocrinology and metabolism. 2013; 305(7):E795–804. Epub 2013/08/08. https://doi.org/10.1152/ajpendo.00257.2013 PMID: 23921137

39. Li Z, Zhang H, Liu J, Liang CP, Li Y, Li Y, et al. Reducing plasma membrane sphingomyelin increases insulin sensitivity. Molecular and cellular biology. 2011; 31(20):4205–18. Epub 2011/08/17. https://doi.org/10.1128/MCB.05893-11 PMID: 21844222

40. Zeghari N, Youinsi M, Meyer L, Donner M, Drouin P, Ziegler O. Adipocyte and erythrocyte plasma membrane phospholipid composition and hyperinsulinemia: a study in nondiabetic and diabetic obese women. Int J Obes Relat Metab Disord. 2000; 24(12):1600–7. Epub 2000/12/29. PMID: 11126212

41. Jeong T, Schissel SL, Tabas I, Pownall HJ, Tall AR, Jiang X. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest. 1998; 101(4):905–12. Epub 1998/03/21. https://doi.org/10.1172/JCI870 PMID: 9466986
42. Micheli H, Carlson LA, Hallberg D. Comparison of lipolysis in human subcutaneous and omental adipose tissue with regard to effects of noradrenaline, theophylline, prostaglandin E1 and age. Acta chirurgica Scandinavica. 1969; 135(8):663–70. Epub 1969/01/01. PMID: 5368951

43. Bergman RN. New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent progress in hormone research. 1997; 52:359–85; discussion 85–7. Epub 1997/01/01. PMID: 9238859

44. Kurland IJ, Accili D, Burant C, Fischer SM, Kahn BB, Newgard CB, et al. Application of combined omics platforms to accelerate biomedical discovery in diabesity. Annals of the New York Academy of Sciences. 2013; 1287:1–16. Epub 2013/05/11. https://doi.org/10.1111/nyas.12116 PMID: 23659636